基本信息
views: 484
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr. Kirkwood received his medical degree in 1973 from Yale University and completed postgraduate work at Yale-New Haven Hospital and then Harvard University and Dana-Farber Cancer Center. After forming the Yale Melanoma Unit he joined the University of Pittsburgh Cancer Institute in 1986 as Founding Associate Director and Chief of Medical Oncology, and the Director of the Melanoma Center. He has been Professor of Medicine, Dermatology, and Translational Science at the University of Pittsburgh, and the Senior Investigator for the University in ECOG, as well as Chairman of the Melanoma Committee of ECOG-ACRIN. He is also the Chairman of the International Melanoma Working Group founded with the Aim at Melanoma foundation in 2006. He has been the Principal Investigator of the Specialized Program of Research Excellence in Melanoma and Skin Cancer since 2008.
Dr. Kirkwood’s research has focused on melanoma, a cancer that afflicts 60,000 and kills more than 8,000 in the United States each year. Under Dr. Kirkwood’s direction, the Melanoma Center has developed new and effective treatment approaches for this disease. He has received international acclaim for leading a multicenter study developed on the basis of his pioneering work with immunomodulators for melanoma that provided the first FDA-approved adjuvant therapy of melanoma in 1996. He has led more than 160 trials over the past 25 years evaluating cytotoxic, molecular, and immunomodulator therapies including vaccines for metastatic and high-risk melanoma. His research has focused upon the analysis of the molecular and immunologic basis of melanoma progression, in studies that have focused upon advanced and adjuvant disease therapy, using novel designs including the first neoadjuvant applications of IFN and ipilimumab. He has developed prognostic and predictive biomarkers that may allow us to refine application of existing and novel therapies.
Dr. Kirkwood has is leading a number of highly promising clinical trials with cancer vaccines, using biological response modifiers, to spur the body’s own immune system to recognize and destroy melanoma. Since his appointment as Director of the Melanoma Center, he has been pursuing translational investigations of immunotherapies and molecularly targeted agents, alone and in combination with one another. Phase I-II and III studies of cytokines, IFNs, antibodies and vaccines have systematically evaluated therapeutic mechanisms and the induction of antitumor and autoimmunity and the use of neoadjuvant trial designs has identified the importance of STAT signaling and immune cell infiltrates as markers of IFN and anti-CTLA4 blocking antibody efficacy, to accelerate progress from phase I-II into phase III national and international studies, and to refine and optimize application of available agents on the basis of these translational studies in human melanoma
Dr. Kirkwood conducts laboratory research on the molecular and biological changes in atypical nevi, as non-obligate precursors and risk markers of melanoma. These studies seek to providing means for earlier detection and prevention of this cancer.
Research Interests
Papers共 971 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Cancer immunology research (2024)
NEW ENGLAND JOURNAL OF MEDICINE (2024)
EClinicalMedicine (2024): 102616
Cited0Views0Bibtex
0
0
Ankit Mangla, Chanmi Lee,Matthew M. Mirsky,Margaret Wang,Luke D. Rothermel,Richard Hoehn,Jeremy S. Bordeaux,Bryan T. Carrol, Jason Theuner,Shawn Li,Pingfu Fu,John M. Kirkwood
JAMA oncologyno. 5 (2024): 612-620
The oncologistno. 7 (2024): 619-628
Future oncology (London, England)no. 15 (2024): 959-968
crossref(2024)
Nature Medicineno. 3 (2024): 906-906
Cited0Views0Bibtex
0
0
Oncotargetno. 1 (2024): 328-344
Load More
Author Statistics
#Papers: 968
#Citation: 63877
H-Index: 111
G-Index: 238
Sociability: 9
Diversity: 0
Activity: 7
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn